Zacks Investment Research upgraded shares of Unum Therapeutics (NASDAQ:UMRX) from a hold rating to a strong-buy rating in a research note released on Saturday, Zacks.com reports. They currently have $1.75 target price on the stock.
According to Zacks, “Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company’s program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. “
Other equities research analysts have also issued reports about the company. ValuEngine upgraded Unum Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. Cowen reiterated a hold rating on shares of Unum Therapeutics in a research note on Monday, August 12th. Wedbush cut their price objective on Unum Therapeutics from $20.00 to $13.00 and set an outperform rating for the company in a research note on Tuesday, August 13th. They noted that the move was a valuation call. HC Wainwright reiterated a buy rating on shares of Unum Therapeutics in a research note on Tuesday, August 13th. Finally, SunTrust Banks cut their price objective on Unum Therapeutics to $6.00 and set a buy rating for the company in a research note on Wednesday, July 3rd. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $9.69.
Unum Therapeutics (NASDAQ:UMRX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. Unum Therapeutics had a negative return on equity of 75.60% and a negative net margin of 340.49%. The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.10 million. On average, sell-side analysts expect that Unum Therapeutics will post -1.24 EPS for the current year.
A number of large investors have recently bought and sold shares of the business. Acadian Asset Management LLC grew its position in shares of Unum Therapeutics by 134.8% in the second quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock valued at $85,000 after purchasing an additional 18,717 shares in the last quarter. Paloma Partners Management Co purchased a new stake in shares of Unum Therapeutics in the second quarter valued at approximately $227,000. Jane Street Group LLC purchased a new stake in shares of Unum Therapeutics in the second quarter valued at approximately $132,000. Susquehanna International Group LLP purchased a new stake in shares of Unum Therapeutics in the second quarter valued at approximately $62,000. Finally, Wedbush Securities Inc. purchased a new stake in shares of Unum Therapeutics in the third quarter valued at approximately $48,000. Institutional investors own 41.95% of the company’s stock.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Further Reading: Short Selling Stocks and Day Traders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.